Literature DB >> 7672063

Prevalence of HBV, HDV and HCV hepatitis markers in HIV-positive patients.

D Francisci1, F Baldelli, R Papili, G Stagni, S Pauluzzi.   

Abstract

Since HIV infection could condition the natural history of parenterally transmitted viral hepatitis (HBV, HCV, HDV), with possibly differing effects in different risk groups, we decided to retrospectively examine sera from a cohort of 637 HIV seropositive patients in different stages of infection, seen from 1985 to 1992, to study the prevalence and temporal course of these infections. Virological markers of HBV, HCV and HDV were determined by ELISA and RIBA methods. The severity of HIV infection was higher in homosexuals than in drug addicts. Prevalence of antiHBc antibodies was 82% in drug addicts and 77% in homosexuals, whereas antiHCV antibodies prevalence was 72% in drug addicts and only 7% in homosexuals (p < 0.000001). When only antiHBc-positive patients were considered, there was a significant difference in antiHBs antibodies between drug addicts (DA) and homosexuals (OR for DA 0.29, 95% CI 0.08/0.83, p = 0.02), suggesting that drug addicts are less able to produce a protective response. This fact cannot be explained by the severity of HIV infection (which was higher among the homosexual group) and suggests some immunodepressive effect of drug abuse. Delta infection was only detected in the drug addict group, and the prevalence was low. Finally, we cannot confirm the interference of HCV infection with the speed of HBsAg clearance: in this study the prevalence of HBsAg was almost the same in HCV-positive and negative patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7672063     DOI: 10.1007/bf01719475

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  21 in total

1.  Second generation (RIBA) test in diagnosis of chronic hepatitis C.

Authors:  P Marcellin; M Martinot-Peignoux; N Boyer; M Pouteau; P Aumont; S Erlinger; J P Benhamou
Journal:  Lancet       Date:  1991-03-02       Impact factor: 79.321

2.  Antibodies to hepatitis C virus in Italian blood donors.

Authors:  G Sirchia; A Bellobuono; A Giovanetti; M Marconi
Journal:  Lancet       Date:  1989-09-30       Impact factor: 79.321

3.  Prevalence, incidence, and risk factors of hepatitis C virus infection among drug users in Amsterdam.

Authors:  J A van den Hoek; H J van Haastrecht; J Goudsmit; F de Wolf; R A Coutinho
Journal:  J Infect Dis       Date:  1990-10       Impact factor: 5.226

4.  The Walter Reed staging classification for HTLV-III/LAV infection.

Authors:  R R Redfield; D C Wright; E C Tramont
Journal:  N Engl J Med       Date:  1986-01-09       Impact factor: 91.245

5.  Immunologic dysfunction in heroin addicts.

Authors:  S M Brown; B Stimmel; R N Taub; S Kochwa; R E Rosenfield
Journal:  Arch Intern Med       Date:  1974-12

6.  Epidemiology of the delta agent: an introduction.

Authors:  R H Purcell; J L Gerin
Journal:  Prog Clin Biol Res       Date:  1983

7.  Prevalence of hepatitis C virus antibodies among patients infected with human immunodeficiency virus.

Authors:  P H Hayashi; N Flynn; S A McCurdy; I K Kuramoto; P V Holland; J B Zeldis
Journal:  J Med Virol       Date:  1991-03       Impact factor: 2.327

8.  Low risk of sexual transmission of hepatitis C virus.

Authors:  N F Hallam; M L Fletcher; S J Read; A M Majid; J B Kurtz; C R Rizza
Journal:  J Med Virol       Date:  1993-07       Impact factor: 2.327

9.  Role of hepatitis C virus infection in spontaneous hepatitis B surface antigen clearance during chronic hepatitis B virus infection.

Authors:  I S Sheen; Y F Liaw; C M Chu; C C Pao
Journal:  J Infect Dis       Date:  1992-05       Impact factor: 5.226

10.  The influence of HTLV-III infection on the natural history of hepatitis B virus infection in male homosexual HBsAg carriers.

Authors:  K Krogsgaard; B O Lindhardt; J O Nielson; P Andersson; P Kryger; J Aldershvile; J Gerstoft; C Pedersen
Journal:  Hepatology       Date:  1987 Jan-Feb       Impact factor: 17.425

View more
  8 in total

1.  Liver Function Tests Abnormalities and Hepatitis B Virus & Hepatitis C Virus Co-infection in Human Immunodeficiency Virus (HIV)-infected Patients in India.

Authors:  P Puri; P K Sharma; A Lolusare; V K Sashindran; S Shrivastava; A K Nagpal
Journal:  J Clin Exp Hepatol       Date:  2016-12-29

2.  A cross-sectional study of liver function tests in HIV-infected persons in Western India.

Authors:  Sunny Pathania; Navjyot Kaur; Sandeep Kumar; V K Sashindran; Pankaj Puri
Journal:  Med J Armed Forces India       Date:  2017-01-07

3.  Measures to reduce HIV infection have not been successful to reduce the prevalence of HCV in intravenous drug users.

Authors:  I Hernandez-Aguado; J M Ramos-Rincon; M J Aviñio; J Gonzalez-Aracil; S Pérez-Hoyos; M G de la Hera
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

4.  Hepatitis B Virus-HIV Coinfection: Forgotten but Not Gone.

Authors:  Narayan Dharel; Richard K Sterling
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-12

5.  Prevalence of serologic markers of HBV, HDV, HCV and HIV in non-injection drug users compared to injection drug users in Gran Canaria, Spain.

Authors:  O E Santana Rodríguez; M L Malé Gil; J F HernándezSantana; J M Limiñana Cañal; A M Martín Sánchez
Journal:  Eur J Epidemiol       Date:  1998-09       Impact factor: 8.082

6.  Infection with HIV and hepatitis C virus among injecting drug users in a prevention setting: retrospective cohort study.

Authors:  I van Beek; R Dwyer; G J Dore; K Luo; J M Kaldor
Journal:  BMJ       Date:  1998-08-15

7.  Prevalence of hepatitis B and C markers in high-risk hospitalised patients in Crete: a five-year observational study.

Authors:  M Koulentaki; M Ergazaki; J Moschandrea; S Spanoudakis; N Tzagarakis; P E Drandakis; D A Spandidos; E A Kouroumalis
Journal:  BMC Public Health       Date:  2001-12-21       Impact factor: 3.295

Review 8.  Liver involvement in human immunodeficiency virus infection.

Authors:  Pankaj Puri; Sandeep Kumar
Journal:  Indian J Gastroenterol       Date:  2016-06-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.